Search

Your search keyword '"Alejandra Goldman"' showing total 11 results
Start Over Author "Alejandra Goldman" Publication Year Range Last 10 years
11 results on '"Alejandra Goldman"'

1. Azelastine potentiates antiasthmatic dexamethasone effect on a murine asthma model

Author

Carlos D. Zappia, Ariadna Soto, Gina Granja‐Galeano, Ignacio Fenoy, Natalia Fernandez, Carlos A. Davio, Carina Shayo, Carlos P. Fitzsimons, Alejandra Goldman, and Federico Monczor

Subjects
antihistamines, asthma, azelastine, dexamethasone, glucocorticoids, histamine, Therapeutics. Pharmacology, RM1-950
Abstract

Abstract Glucocorticoids are among the most effective drugs to treat asthma. However, the severe adverse effects associated generate the need for its therapeutic optimization. Conversely, though histamine is undoubtedly related to asthma development, there is a lack of efficacy of antihistamines in controlling its symptoms, which prevents their clinical application. We have reported that antihistamines potentiate glucocorticoids’ responses in vitro and recent observations have indicated that the coadministration of an antihistamine and a synthetic glucocorticoid has synergistic effects on a murine model of allergic rhinitis. Here, the aim of this work is to establish if this therapeutic combination could be beneficial in a murine model of asthma. We used an allergen‐induced model of asthma (employing ovalbumin) to evaluate the effects of the synthetic glucocorticoid dexamethasone combined with the antihistamine azelastine. Our results indicate that the cotreatment with azelastine and a suboptimal dose of dexamethasone can improve allergic lung inflammation as shown by a decrease in eosinophils in bronchoalveolar lavage, fewer peribronchial and perivascular infiltrates, and mucin‐producing cells. In addition, serum levels of allergen‐specific IgE and IgG1 were also reduced, as well as the expression of lung inflammatory‐related genes IL‐4, IL‐5, Muc5AC, and Arginase I. The potentiation of dexamethasone effects by azelastine could allow to reduce the effective glucocorticoid dose needed to achieve a therapeutic effect. These findings provide first new insights into the potential benefits of glucocorticoids and antihistamines combination for the treatment of asthma and grants further research to evaluate this approach in other related inflammatory conditions.

Published
2019
Full Text
View/download PDF

2. Toxoplasma gondii serine-protease inhibitor-1: A new adjuvant candidate for asthma therapy.

Author

Ariadna S Soto, Ignacio M Fenoy, Vanesa R Sanchez, Florencia March, Matías D Perrone Sibilia, María de Los Angeles Aldirico, Mariano S Picchio, Nadia Arcon, Patricio L Acosta, Fernando P Polack, Valentina Martin, and Alejandra Goldman

Subjects
Medicine, Science
Abstract

Serine-proteases are important players in the pathogenesis of asthma, promoting inflammation and tissue remodeling. It's also known that many serine protease inhibitors display immunomodulatory properties. TgPI-1 is a Toxoplasma gondii protein that exhibits broad spectrum inhibitory activity against serine proteases. In view of the increased prevalence of atopic disorders and the need to develop new treatment strategies we sought to investigate the potential of TgPI-1 for treating respiratory allergies. For this purpose, we developed a therapeutic experimental model. BALB/c mice were rendered allergic by intraperitoneal ovalbumin-alum sensitization and airway-challenged. Once the asthmatic phenotype was achieved, mice were intranasally treated with rTgPI-1 alone or with a mixture of rTgPI-1 and ovalbumin (OVA). A week later mice were given a secondary aerosol challenge. Treatment with rTgPI-1 alone or co-administered with OVA diminished bronchoalveolar eosinophilia, mucus production and peribronchial lung infiltration. This effect was accompanied by a lung resistance reduction of 26.3% and 50.3% respectively. Both treatments resulted in the production of lower levels of IL-4, IL-5, IFN-γ and regulatory IL-10 by thoracic lymph node cells stimulated with OVA. Interestingly, significant decreases in OVA specific IgE and T cell proliferation, and increases in FoxP3+ T cells at local and systemic levels were only detected when the inhibitor was administered along with OVA. These results show that both rTgPI-1 treatments reduced asthma hallmarks. However, co-administration of the inhibitor with the allergen was more effective. Hence, rTgPI-1 emerges as a novel adjuvant candidate for asthma treatment.

Published
2017
Full Text
View/download PDF

3. Contribution of Kazal-Like Domains of the Serine Protease Inhibitor-1 from Toxoplasma gondii in Asthma Therapeutic Vaccination Effectiveness

Author

Ariadna Soto, Matías Perrone Sibilia, Vanesa Roxana Sánchez, Nadia Arcón, Valentina Martin, Ignacio Martín Fenoy, and Alejandra Goldman

Subjects
Immunology, Immunology and Allergy, General Medicine
Abstract

Background: We have previously showed rTgPI-1 tolerogenic adjuvant properties in asthma treatment, turning it a promising candidate for allergen-specific immunotherapy. This therapy is an alternative treatment to control asthma that still presents several concerns related to its formulation. rTgPI-1 contains independent inhibitory domains able to inhibit trypsin and neutrophil elastase, both involved in asthma pathology. Objectives: In view of the need to design rational therapies, herein we investigated the contribution of the different inhibitory domains in rTgPI-1 therapeutic effectiveness. Methods: BALB/c mice were rendered allergic by intraperitoneal OVA-alum sensitization and airway challenged. Once the asthmatic phenotype was achieved, mice were intranasally treated with OVA combined with the full-length recombinant protein rTgPI-1 or its truncated versions, Nt (containing trypsin-inhibitory domains) or Ct (containing neutrophil elastase-inhibitory domains). Afterward, mice were aerosol re-challenged. Results: Asthmatic mice treated with the neutrophil elastase- or the trypsin-inhibitory domains separately failed to improve allergic lung inflammation. Only when all inhibitory domains were simultaneously administered, an improvement was achieved. Still, a better outcome was obtained when mice were treated with the full-length rTgPI-1. Conclusions: Adjuvant ability depends on the presence of all its inhibitory domains in a single entity, so it should be included in potential asthma treatment formulations as a full-length protein.

Published
2022
Full Text
View/download PDF

4. Synergistic effect of GRA7 and profilin proteins in vaccination against chronic Toxoplasma gondii infection

Author

Valentina Martin, Cecilia A. Prato, Mariano Sergio Picchio, Ariadna Soledad Soto, Ignacio Martín Fenoy, Nadia Arcon, Alejandra Goldman, Rosalia Moretta, María Virginia Tribulatti, Vanesa Roxana Sánchez, and Matías D. Perrone Sibilia

Subjects
Protozoan Vaccines, Cellular immunity, 030231 tropical medicine, Protozoan Proteins, Antibodies, Protozoan, Antigens, Protozoan, Lymphocyte proliferation, Mice, Profilins, 03 medical and health sciences, 0302 clinical medicine, Immune system, Antigen, Immunity, Animals, 030212 general & internal medicine, Mice, Inbred BALB C, Innate immune system, General Veterinary, General Immunology and Microbiology, biology, Vaccination, Public Health, Environmental and Occupational Health, Toxoplasma gondii, biology.organism_classification, Toxoplasmosis, Animal, Infectious Diseases, Immunology, Cytokines, Molecular Medicine, Toxoplasma
Abstract

Toxoplasmosis is a zoonotic disease with worldwide prevalence in humans and warm-blooded animal populations. In livestock Toxoplasma gondii is the causal agent of significant economic losses since it can cause abortions in goats and sheep. It is estimated that one third of the world population is infected. Although there are effective therapies for acute infection, these are sometimes poorly tolerated, teratogenic, and have a long administration time. Considering the deficiencies that exist related to the prevention and treatment of toxoplasmosis, the development of a safe and effective vaccine would be extremely valuable in fighting against this infection. In the present work, we characterize for the first time the adjuvant and immunogenic potential of a recombinant profilin protein (rTgPF), in a vaccine formulation alone or in combination with the well-known GRA7 antigen candidate in a murine toxoplasmosis model. Since TgPF acts as a ligand for TLR11 and 12 inducing innate immune responses that promote type 1 adaptive responses, we first study the capacity of the mix rGRA7 + rTgPF to initiate an immune response by evaluating dendritic cell activation. Both rTgPF and rGRA7 induces activation of mouse BMDCs more efficiently than the single proteins, evidenced by increased expression of CD80 and CD86 co-stimulatory proteins and secretion of IL-6, IL-10 and IL-12 cytokines after in vitro stimulation. The sum of the effects of rGRA7 and rTgPF on BMDCs maturation led us to assay them in a vaccination protocol. BALB/c mice vaccinated with this mix elicited a Th1-biased immunity via the induction of lymphocyte proliferation, activation of CD4+T cells and increased IFN-γ production that resulted in enhanced protection against chronic Toxoplama gondii infection. Profilin per se induce only cellular immunity but augments the effect of rGRA7 immune responses when used together, thus allowing us to postulate rTgPF as a potential adjuvant in a protein vaccine.

Published
2021
Full Text
View/download PDF

6. Chronic infection with the protozoan Toxoplasma gondii prevents the development of experimental atopic dermatitis in mice

Author

Ignacio Martín Fenoy, Ariadna Soledad Soto, Mariano Sergio Picchio, Valentina Martin, Nadia Arcon, Silvia Vanzulli, María de los Angeles Aldirico, Alejandra Goldman, Rosalia Moretta, Vanesa Roxana Sánchez, and Matías D. Perrone Sibilia

Subjects
0301 basic medicine, Allergy, medicine.medical_treatment, Dermatology, medicine.disease_cause, Biochemistry, Dermatitis, Atopic, Allergic sensitization, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Allergen, medicine, Animals, Molecular Biology, Mice, Inbred BALB C, Innate immune system, biology, business.industry, Toxoplasma gondii, Atopic dermatitis, biology.organism_classification, medicine.disease, Chronic infection, 030104 developmental biology, Cytokine, Immunology, Chronic Disease, business, Toxoplasma, Toxoplasmosis
Abstract

Background Supporting the hypothesis thatT. gondii infection protects against allergy in humans we previously demonstrated that this infection can modulate not only the susceptibility to develop respiratory allergies in mice but also suppresses allergic responses at systemic level. This latter finding suggests that T. gondii infection could prevent the onset of other allergic diseases, such as atopic dermatitis. At present, few studies have investigated the modulation of atopic dermatitis by parasite infections. Objective Here, we sought to investigate whether chronic infection with T. gondii is capable of modulating the development of atopic dermatitis. Methods Chronically infected mice were sensitized by repeated epicutaneous ovalbumin administration. Skin histopathology, humoral response, cytokine production and innate type-II lymphoid cells (ILC2) were assessed. Results A marked reduction in epidermal thickness and dermal inflammatory infiltrate along with a reduction in mast cell count was observed in infected mice compared to non-infected mice. These results correlated with a diminished TH2 and TH1 allergen specific response. Reduced type-II IL-4 and IL-5 cytokines were already detected during the first 24 h of allergen sensitization in splenocytes and draining lymph nodes from infected mice. Moreover, this reduced type-II profile in chronically infected animals correlated with diminished ILC2 number in draining lymph nodes. Conclusion Chronic infection withT. gondii prevents the development of atopic dermatitis. The diminished susceptibility seems to result from changes in type-II innate immune response that may lead to the induction of a deficient TH2 response and consequently to a lower susceptibility to develop atopic dermatitis.

Published
2019

7. Genotyping of Toxoplasma gondii: The advantages of variable number tandem repeats within coding regions

Author

Rosalia Moretta, Valentina Martin, Vanesa Roxana Sánchez, Alejandra Goldman, Paula Ruybal, and Ignacio Martín Fenoy

Subjects
0301 basic medicine, Microbiology (medical), Genotyping Techniques, Minisatellite Repeat, 030106 microbiology, Minisatellite Repeats, Microbiology, Genome, 03 medical and health sciences, Tandem repeat, parasitic diseases, Genetic variation, Chlorocebus aethiops, Genetics, Animals, Molecular Biology, Genotyping, Vero Cells, Ecology, Evolution, Behavior and Systematics, Polymorphism, Genetic, biology, Toxoplasma gondii, Genetic Variation, biology.organism_classification, Variable number tandem repeat, 030104 developmental biology, Infectious Diseases, Genetic marker, Toxoplasma
Abstract

Toxoplasma gondii is an intracellular protozoan which is widely distributed. Infection occurs as a result of ingestion of uncooked meat and exposure to cat feces. Immunocompetent individuals are generally asymptomatic, while severe disease may occur in immunocompromised subjects and in congenital toxoplasmosis, which is caused by transplacental acquisition of T. gondii. Genetic diversity of T. gondii has often been studied using a PCR-RFLP scheme based on nine molecular markers. These studies led to the description of a clonal population structure with three main lineages (I, II and III) in North America and Europe and higher genetic diversity in South America. The aim of this study was to develop molecular markers that could allow the discrimination of genetic variants within each clonal lineage. We analyzed the genome of T. gondii to identify genes containing variable number tandem repeats (VNTRs). The coding sequences of T. gondii ME49 genome were processed with Tandem Repeat Finder software. A panel of candidate markers was selected based on the following parameters: the repeat unit size (>9 bp) and composition (to avoid single and dinucleotide runs), the number of copies (

Published
2017

8. Vaccine potential of antigen cocktails composed of recombinant Toxoplasma gondii TgPI-1, ROP2 and GRA4 proteins against chronic toxoplasmosis in C3H mice

Author

Mariano Sergio Picchio, Valentina Martin, Nadia Arcon, Alejandra Goldman, Vanesa Roxana Sánchez, Mariela Urrutia, María de los Angeles Aldirico, Rosalia Moretta, Ignacio Martín Fenoy, Matías D. Perrone Sibilia, and Ariadna Soledad Soto

Subjects
0301 basic medicine, Male, Protozoan Vaccines, 030106 microbiology, Immunology, Foreskin, Protozoan Proteins, Antibodies, Protozoan, Spleen, Antigens, Protozoan, Immunoglobulin G, Cell Line, 03 medical and health sciences, Mice, Immune system, Antigen, Intestinal mucosa, medicine, Animals, Humans, Intestinal Mucosa, Mice, Inbred C3H, Vaccines, Synthetic, biology, Toxoplasma gondii, Membrane Proteins, General Medicine, Fibroblasts, biology.organism_classification, medicine.disease, Toxoplasmosis, 030104 developmental biology, Infectious Diseases, medicine.anatomical_structure, Toxoplasmosis, Animal, Chronic Disease, Immunoglobulin A, Secretory, biology.protein, Cytokines, Parasitology, Female, Antibody, Toxoplasma
Abstract

The development of an effective and safe vaccine to prevent Toxoplasma gondii infection is an important aim due to the great clinical and economic impact of this parasitosis. We have previously demonstrated that immunization with the serine protease inhibitor-1 (TgPI-1) confers partial protection to C3H/HeN and C57BL/6 mice. In order to improve the level of protection, in this work, we combined this novel antigen with ROP2 and/or GRA4 recombinant proteins (rTgPI-1+rROP2, rTgPI-1+rGRA4, rTgPI-1+rROP2+rGRA4) to explore the best combination against chronic toxoplasmosis in C3H/HeN mice. All tested vaccine formulations, administered following a homologous prime-boost protocol that combines intradermal and intranasal routes, conferred partial protection as measured by the reduction of brain cyst burden following oral challenge with tissue cysts of Me49 T. gondii strain. The highest level of protection was achieved by the mixture of rTgPI-1 and rROP2 proteins with an average parasite burden reduction of 50% compared to the unvaccinated control group. The vaccine-induced protective effect was related to the elicitation of systemic cellular and humoral immune responses that included antigen-specific spleen cell proliferation, the release of Th1/Th2 cytokines, and the generation of antigen-specific antibodies in serum. Additionally, mucosal immune responses were also induced, characterized by secretion of antigen-specific IgA antibodies in intestinal lavages and specific mesenteric lymph node cell proliferation. Our results demonstrate that rTgPI-1+rROP2 antigens seem a promising mixture to be combined with other immunogenic proteins in a multiantigenic vaccine formulation against toxoplasmosis.

Published
2017

9. Toxoplasma gondii serine-protease inhibitor-1: A new adjuvant candidate for asthma therapy

Author

Valentina Martin, Florencia March, Ignacio Martín Fenoy, Mariano Sergio Picchio, Fernando P. Polack, María de los Angeles Aldirico, Vanesa Roxana Sánchez, Ariadna Soledad Soto, Nadia Arcon, Alejandra Goldman, Patricio L. Acosta, and Matías D. Perrone Sibilia

Subjects
0301 basic medicine, Allergy, Pulmonology, Physiology, medicine.medical_treatment, Antibodies, Protozoan, lcsh:Medicine, Pathology and Laboratory Medicine, Immunoglobulin E, T-Lymphocytes, Regulatory, Biochemistry, Mice, White Blood Cells, 0302 clinical medicine, Antibody Specificity, Animal Cells, Immune Physiology, Allergies, Medicine and Health Sciences, Eosinophilia, Drug Interactions, ADJUVANT CANDIDATE, lcsh:Science, Immune Response, Mice, Inbred BALB C, Innate Immune System, SERIN PROTEASE INHIBITOR, Multidisciplinary, biology, T Cells, FOXP3, Forkhead Transcription Factors, Proteases, Animal Models, purl.org/becyt/ford/3.1 [https], respiratory system, Recombinant Proteins, Enzymes, Medicina Básica, medicine.anatomical_structure, Experimental Organism Systems, Cytokines, purl.org/becyt/ford/3 [https], Cellular Types, medicine.symptom, Toxoplasma, Research Article, CIENCIAS MÉDICAS Y DE LA SALUD, Serine Proteinase Inhibitors, Ovalbumin, Immune Cells, Inflammatory Diseases, T cell, Immunology, Inmunología, Mouse Models, Research and Analysis Methods, 03 medical and health sciences, Signs and Symptoms, Model Organisms, Diagnostic Medicine, medicine, Animals, IMMUNOTHERAPY, ASTHMA THERAPY, Cell Proliferation, Inflammation, Blood Cells, business.industry, lcsh:R, Biology and Life Sciences, Proteins, Cell Biology, Immunotherapy, Allergens, Molecular Development, medicine.disease, Asthma, 030104 developmental biology, 030228 respiratory system, Immune System, Enzymology, biology.protein, Clinical Immunology, lcsh:Q, Clinical Medicine, Serine Proteases, business, Developmental Biology
Abstract

Serine-proteases are important players in the pathogenesis of asthma, promoting inflammation and tissue remodeling. It’s also known that many serine protease inhibitors display immunomodulatory properties. TgPI-1 is a Toxoplasma gondii protein that exhibits broad spectrum inhibitory activity against serine proteases. In view of the increased prevalence of atopic disorders and the need to develop new treatment strategies we sought to investigate the potential of TgPI-1 for treating respiratory allergies. For this purpose, we developed a therapeutic experimental model. BALB/c mice were rendered allergic by intraperitoneal ovalbumin-alum sensitization and airway-challenged. Once the asthmatic phenotype was achieved, mice were intranasally treated with rTgPI-1 alone or with a mixture of rTgPI-1 and ovalbumin (OVA). A week later mice were given a secondary aerosol challenge. Treatment with rTgPI-1 alone or co-administered with OVA diminished bronchoalveolar eosinophilia, mucus production and peribronchial lung infiltration. This effect was accompanied by a lung resistance reduction of 26.3% and 50.3% respectively. Both treatments resulted in the production of lower levels of IL-4, IL-5, IFN-γ and regulatory IL-10 by thoracic lymph node cells stimulated with OVA. Interestingly, significant decreases in OVA specific IgE and T cell proliferation, and increases in FoxP3+ T cells at local and systemic levels were only detected when the inhibitor was administered along with OVA. These results show that both rTgPI-1 treatments reduced asthma hallmarks. However, co-administration of the inhibitor with the allergen was more effective. Hence, rTgPI-1 emerges as a novel adjuvant candidate for asthma treatment. Fil: Soto, Ariadna Soledad. Universidad Nacional de San Martín. Escuela de Ciencia y Tecnología. Centro de Estudios en Salud y Medio Ambiente; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Fenoy, Ignacio Martín. Universidad Nacional de San Martín. Escuela de Ciencia y Tecnología. Centro de Estudios en Salud y Medio Ambiente; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Sánchez, Vanesa Roxana. Universidad Nacional de San Martín. Escuela de Ciencia y Tecnología. Centro de Estudios en Salud y Medio Ambiente; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Marchini, Florencia. Universidad Nacional de San Martín. Escuela de Ciencia y Tecnología. Centro de Estudios en Salud y Medio Ambiente; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Perrone Sibilia, Matias. Universidad Nacional de San Martín. Escuela de Ciencia y Tecnología. Centro de Estudios en Salud y Medio Ambiente; Argentina Fil: Aldirico, María de Los Ángeles. Universidad Nacional de San Martín. Escuela de Ciencia y Tecnología. Centro de Estudios en Salud y Medio Ambiente; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Picchio, Mariano Sergio. Universidad Nacional de San Martín. Escuela de Ciencia y Tecnología. Centro de Estudios en Salud y Medio Ambiente; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Arcon, Nadia. Universidad Nacional de San Martín. Escuela de Ciencia y Tecnología. Centro de Estudios en Salud y Medio Ambiente; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Acosta, Patricio Leandro. Fundación para la Investigación en Infectología Infantil; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Polack, Fernando Pedro. Fundación para la Investigación en Infectología Infantil; Argentina Fil: Martín, Valentina. Universidad Nacional de San Martín. Escuela de Ciencia y Tecnología. Centro de Estudios en Salud y Medio Ambiente; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Goldman, Alejandra. Universidad Nacional de San Martín. Escuela de Ciencia y Tecnología. Centro de Estudios en Salud y Medio Ambiente; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina

Published
2017

10. Homologous prime-boost strategy with TgPI-1 improves the immune response and protects highly susceptible mice against chronic Toxoplasma gondii infection

Author

Nadia Arcon, Vanesa Roxana Sánchez, Valentina Martin, Alejandra Goldman, Ignacio Martín Fenoy, Mariano Sergio Picchio, and Ariadna Soledad Soto

Subjects
Protozoan Vaccines, Adoptive cell transfer, CIENCIAS MÉDICAS Y DE LA SALUD, Injections, Subcutaneous, Veterinary (miscellaneous), Protozoan Proteins, Ciencias de la Salud, Biology, Drug Administration Schedule, Toxoplasma Gondii, Mice, Prime-Boost Strategy, Immune system, Serin Proteasa Inhibitor-1, Adjuvants, Immunologic, medicine, Animals, Mucosal Immunity, Parasitología, Immunity, Mucosal, Lymph node, Pathogen, Administration, Intranasal, Subunit Vaccine, Vaccination, Toxoplasma gondii, biology.organism_classification, Virology, Mice, Inbred C57BL, Chronic infection, Toxoplasmosis, Animal, Infectious Diseases, medicine.anatomical_structure, Insect Science, Immunology, Alum Compounds, Female, Parasitology, Nasal administration, Toxoplasma
Abstract

Subunit-based vaccines are safer than live or attenuated pathogen vaccines, although they are generally weak immunogens. Thus, proper combination of immunization strategies and adjuvants are needed to increase their efficacy. We have previously protected C3H/HeN mice from Toxoplasma gondii infection by immunization with the serine protease inhibitor-1 (TgPI-1) in combination with alum. In this work, we explore an original vaccination protocol that combines administration of recombinant TgPI-1 by intradermal and intranasal routes in order to enhance protection in the highly susceptible C57BL/6 strain. Mice primed intradermally with rTgPI-1 plus alum and boosted intranasally with rTgPI-1 plus CpG-ODN elicited a strong specific Th1/Th2 humoral response, along with a mucosal immune response characterized by specific-IgA in intestinal lavages. A positive cellular response of mesentheric lymph node cells and Th1/Th2 cytokine secretion in the ileon were also detected. When immunized mice were challenged with the cystogenic Me49 T. gondii strain, they displayed up to 62% reduction in brain parasite burden. Moreover, adoptive transfer of mesenteric lymph node cells from vaccinated to naïve mice induced significant protection against infection. These results demonstrate that this strategy that combines the administration of TgPI-1 by two different routes, intradermal priming and intranasal boost, improves protective immunity against T. gondii chronic infection in highly susceptible mice. Fil: Sánchez, Vanesa Roxana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de San Martín. Escuela de Ciencia y Tecnología. Centro de Estudios en Salud y Medio Ambiente; Argentina Fil: Fenoy, Ignacio Martín. Universidad Nacional de San Martín. Escuela de Ciencia y Tecnología. Centro de Estudios en Salud y Medio Ambiente; Argentina Fil: Picchio, Mariano Sergio. Universidad Nacional de San Martín. Escuela de Ciencia y Tecnología. Centro de Estudios en Salud y Medio Ambiente; Argentina Fil: Soto, Ariadna Soledad. Universidad Nacional de San Martín. Escuela de Ciencia y Tecnología. Centro de Estudios en Salud y Medio Ambiente; Argentina Fil: Arcon, Nadia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de San Martín. Escuela de Ciencia y Tecnología. Centro de Estudios en Salud y Medio Ambiente; Argentina Fil: Golgman, Alejandra. Universidad Nacional de San Martín. Escuela de Ciencia y Tecnología. Centro de Estudios en Salud y Medio Ambiente; Argentina Fil: Martín, Valentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de San Martín. Escuela de Ciencia y Tecnología. Centro de Estudios en Salud y Medio Ambiente; Argentina

Published
2015

11. La educación como puente: Simmel, la tragedia de la cultura, y el desarrollo significativo del ser

Author

Marina Alejandra Goldman

Subjects
cultura, modernidad, tragedia, pedagogía, educación, Ethics, BJ1-1725, Political science, Philosophy (General), B1-5802
Abstract

Se debate la idea simmeliana de “tragedia de la cultura” en el marco de la relación entre cultura y vida en la modernidad. Complementariamente se indaga el potencial de la pedagogía escolar para, según Simmel, establecer un vínculo entre educación y cultura. Finalmente, se reflexiona sobre las deseables consecuencias que el establecimiento de este vínculo podría acarrear para el aplacamiento de la tragedia moderna descripta por el autor.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results